Alps Group Inc(ALPS)

Biotechnology · Kuala Lumpur, WP

$0.38-0.02 (-4.50%)

Delayed quote: Oct 6, 2026, 2:59 PM EDT

EBITDA Yield: N/A

Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.

The EBITDA yield is N/A as of 2026-10-06T19:00:25.498Z.

Stored calculation inputs

Calculation as of: 2026-10-06T19:00:25.498Z.

Quote observation: 2026-10-06T18:59:41.000Z. Amounts in USD. The price header may show a later quote.

TTM operating EBITDA · period ending 2025-09-30: N/A
Quote market capitalization: 63,564,926
Total debt · period ending 2026-03-31: N/A
Cash · period ending 2026-03-31: N/A

FMP input reference: 473da95602fdb42a5f780e5c02853506da999e38a33e04168dea7648cb5c925f

EV/EBITDA|Earnings Yield|OCF Yield|FCF Yield|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

ALPS EBITDA Yield Metrics

EBITDA YIELD

N/A

ALPS Competitors' EBITDA Yield

ALPS

Alps Group Inc

Current

Market Cap

$63.56M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

INCR

InterCure Ltd.

vs ALPS

Market Cap

$63.19M

EBITDA Yield

N/A

TTM Avg

13.59%

3Y Avg

8.25%

5Y Avg

8.86%

PLRX

Pliant Therapeutics, Inc.

vs ALPS

Market Cap

$63.16M

EBITDA Yield

N/A

TTM Avg

8.85%

3Y Avg

8.85%

5Y Avg

8.85%

RNXT

RenovoRx, Inc.

vs ALPS

Market Cap

$63.52M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

HRTX

Heron Therapeutics, Inc.

vs ALPS

Market Cap

$62.56M

EBITDA Yield

N/A

TTM Avg

0.88%

3Y Avg

0.88%

5Y Avg

0.88%

GOSS

Gossamer Bio, Inc.

vs ALPS

Market Cap

$64.83M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

GUTS

Fractyl Health, Inc.

vs ALPS

Market Cap

$61.34M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

XBIT

XBiotech Inc.

vs ALPS

Market Cap

$65.85M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

KLRS

Kalaris Therapeutics Inc

vs ALPS

Market Cap

$61.01M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

IBIO

iBio, Inc.

vs ALPS

Market Cap

$66.82M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
Alps Group Inc (ALPS)	$63.56M	N/A	N/A	N/A	N/A
InterCure Ltd. (INCR)vs ›	$63.19M	N/A	13.59%	8.25%	8.86%
Pliant Therapeutics, Inc. (PLRX)vs ›	$63.16M	N/A	8.85%	8.85%	8.85%
RenovoRx, Inc. (RNXT)vs ›	$63.52M	N/A	N/A	N/A	N/A
Heron Therapeutics, Inc. (HRTX)vs ›	$62.56M	N/A	0.88%	0.88%	0.88%
Gossamer Bio, Inc. (GOSS)vs ›	$64.83M	N/A	N/A	N/A	N/A
Fractyl Health, Inc. (GUTS)vs ›	$61.34M	N/A	N/A	N/A	N/A
XBiotech Inc. (XBIT)vs ›	$65.85M	N/A	N/A	N/A	N/A
Kalaris Therapeutics Inc (KLRS)vs ›	$61.01M	N/A	N/A	N/A	N/A
iBio, Inc. (IBIO)vs ›	$66.82M	N/A	N/A	N/A	N/A

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EBITDA Yield: N/A

ALPS EBITDA Yield Metrics

ALPS Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics